A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

ClinicalTrials.gov ID: NCT02413827

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02413827. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Safety Pilot/Phase II, Open-label Study of Varlilumab (CDX-1127) in Combination With Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or Stage IV Melanoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining a) varlilumab and ipilimumab and b) varlilumab, ipilimumab, CDX-1401 and poly-ICLC. The study will enroll patients with unresectable Stage III or Stage IV melanoma.

Study identification

NCT ID: NCT02413827
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Celldex Therapeutics; Industry
Enrollment: 9 participants

Conditions and interventions

Conditions

Unresectable Stage III or Stage IV Melanoma

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 2015 (Actual)
Primary completion: Nov 2, 2016 (Actual)
Completion: Nov 9, 2016 (Actual)
Last update posted: Apr 7, 2017

2015 – 2016

United States locations

U.S. sites: 8
U.S. states: 7
U.S. cities: 8

Facility	City	State	ZIP	Site status
California Pacific Medical Center Research Institute	San Francisco	California	94115	—
Sutter Pacific Medical Foundation	Santa Rosa	California	95403	—
University of Colorado	Aurora	Colorado	80045	—
Georgetown University School of Medicine	Washington D.C.	District of Columbia	20007	—
University of Chicago	Chicago	Illinois	60637	—
Washington University School of Medicine	St Louis	Missouri	63110	—
University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania	15232	—
Tennessee Oncology Sarah Cannon Research Institute	Nashville	Tennessee	37203	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02413827, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 7, 2017 · Synced Nov 15, 2026